Discovery of G Protein-Biased EP2 Receptor Agonists

ACS Medicinal Chemistry Letters

Volumn 7, Issue 3, 2016, Pages 306-311

  Ogawa, Seiji ^a,b,d   Watanabe, Toshihide ^a   Sugimoto, Isamu ^a   Moriyuki, Kazumi ^b   Goto, Yoshikazu ^b   Yamane, Shinsaku ^b   Watanabe, Akio ^a   Tsuboi, Kazuma ^a   Kinoshita, Atsushi ^a   Kigoshi, Hideo ^d   Tani, Kousuke ^c   Maruyama, Toru ^a  

^a Medicinal Chemistry Research Laboratories   (Japan)

^b Department of Biology and Pharmacology ^*  (Japan)

^c ONO PHARMACEUTICAL CO   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

agonist; biased ligand; EP2; Prostaglandin; structure functional selectivity relationship

Indexed keywords

BETA ARRESTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROSTACYCLIN; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; THIAZOLE;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; HYDROLYSIS; MITSUNOBU REACTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

EID: 84960939804     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00455     Document Type: Article

References (31)

1. Coleman, R. A.; Kennedy, I.; Humphrey, P. P. A.; Bunce, K.; Lumley, P. In Comprehensive Medicinal Chemistry; Hansch, C., Sammes, P. G., Taylor, J. B., Emmett, J. C., Eds.; Pergamon: Oxford, 1990; Vol. 3, pp 643-714.
2. Yoshida, K.; Oida, H.; Kobayashi, T.; Maruyama, T.; Tanaka, M.; Katayama, T.; Yamaguchi, K.; Segi, E.; Tsuboyama, T.; Matsushita, M.; Ito, K.; Ito, Y.; Sugimoto, Y.; Ushikubi, F.; Ohuchida, S.; Kondo, K.; Nakamura, T.; Narumiya, S. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 4580-4585 10.1073/pnas.062053399
3. Katsuyama, M.; Ikegami, R.; Karahashi, H.; Amano, F.; Sugimoto, Y.; Ichikawa, A. Characterization of the LPS-stimulated expression of EP2 and EP4 prostaglandin E receptors in mouse macrophage-like cell line, J774.1 Biochem. Biophys. Res. Commun. 1998, 251, 727-731 10.1006/bbrc.1998.9540
4. Jiang, J.; Dingledine, R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection Trends Pharmacol. Sci. 2013, 34, 413-423 10.1016/j.tips.2013.05.003
5. 2 EP2 receptor in cerebral ischemia J. Neurosci. 2004, 24, 257-268 10.1523/JNEUROSCI.4485-03.2004
6. 2 EP2 receptor in permanent focal cerebral ischemia Ann. Neurol. 2005, 57, 758-761 10.1002/ana.20461
7. 2 receptor agonist, protects against cerebral ischemia Neurosci. Lett. 2008, 438, 210-215 10.1016/j.neulet.2008.04.054
8. 2 EP2 receptor and its selective activation are beneficial against ischemic stroke Exp. Transl. Stroke Med. 2010, 2, 12 10.1186/2040-7378-2-12
9. 2) agonist that induces local bone formation Bioorg. Med. Chem. Lett. 2009, 19, 2075-2078 10.1016/j.bmcl.2009.01.059
10. Tani, K.; Naganawa, A.; Ishida, A.; Egashira, H.; Sagawa, K.; Harada, H.; Ogawa, M.; Maruyama, T.; Ohuchida, S.; Nakai, H.; Kondo, K.; Toda, M. Design and synthesis of a highly selective EP2-receptor agonist Bioorg. Med. Chem. Lett. 2001, 11, 2025-2028 10.1016/S0960-894X(01)00359-6
11. Gardiner, P. J. Characterization of prostanoid relaxant/inhibitory receptors (Ψ) using a highly selective agonist, TR4979 Br. J. Pharmacol. 1986, 87, 45-56 10.1111/j.1476-5381.1986.tb10155.x
12. Old, D. W.; Dinh, D. T. Substituted Gamma Lactams as Therapeutic Agents. Int. Pat. Appl. WO2006098918, 2006.
13. Prasanna, G.; Bosworth, C. F.; Lafontaine, J. A. EP2 agonists. Int. Pat. Appl. WO2008015517, 2008.
14. Hagihara, M.; Yoneda, K.; Okanari, E.; Shigetomi, M. Parmaceutical composition for treating of preventing glaucoma. Int. Pat. Appl. WO2010113957, 2010.
15. Coleman, R.; Middlemiss, D. Difuluorophenylamide derivatives for the treatment of ocular hypertension. Int. Pat. Appl. WO2009098458, 2009.
16. Prasanna, G.; Carreiro, S.; Anderson, S.; Gukasyan, H.; Sartnurak, S.; Younis, H.; Gale, D.; Xiang, C.; Wells, P.; Dinh, D.; Almaden, C.; Fortner, J.; Toris, C.; Niesman, M.; Lafontaine, J.; Krauss, A. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma Exp. Eye Res. 2011, 93, 256-264 10.1016/j.exer.2011.02.015
17. Violin, J. D.; Lefkowitz, R. J. β-arrestin-biased ligands at seven-transmembrane receptors Trends Pharmacol. Sci. 2007, 28, 416-422 10.1016/j.tips.2007.06.006
18. Zhou, L.; Lovell, K. M.; Frankowski, K. J.; Slauson, S. R.; Phillips, A. M.; Streicher, J. M.; Stahl, E.; Schmid, C. L.; Hodder, P.; Madoux, F.; Cameron, M. D.; Prisinzano, T. E.; Aubé, J.; Bohn, L. M. Development of functionally selective, small molecule agonists at kappa opioid receptors J. Biol. Chem. 2013, 288, 36703-36716 10.1074/jbc.M113.504381
19. Correll, C. C.; Mckittrick, B. A. Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery J. Med. Chem. 2014, 57, 6887-6896 10.1021/jm401677g
20. 2 receptor agonists J. Med. Chem. 2012, 55, 7141-7153 10.1021/jm300603y
21. Chen, X. T.; Pitis, P.; Liu, G.; Yuan, C.; Gotchev, D.; Cowan, C. L.; Rominger, D. H.; Koblish, M.; Dewire, S. M.; Crombie, A. L.; Violin, J. D.; Yamashita, D. S. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain J. Med. Chem. 2013, 56, 8019-8031 10.1021/jm4010829
22. Violin, J. D.; DeWire, S. M.; Yamashita, D.; Rominger, D. H.; Nguyen, L.; Schiller, K.; Whalen, E. J.; Gowen, M.; Lark, M. W. Selectively engaging β-Arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance J. Pharmacol. Exp. Ther. 2010, 335, 572-579 10.1124/jpet.110.173005
23. 2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis Ann. Neurol. 2004, 56, 240-248 10.1002/ana.20179
24. Carrasco, E.; Werner, P.; Casper, D. Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress Neurosci. Lett. 2008, 441, 44-49 10.1016/j.neulet.2008.05.111
25. Chun, K. S.; Lao, H. C.; Trempus, C. S.; Okada, M.; Langenbach, R. The prostaglandin receptor EP2 activates multiple signaling pathways and β-arrestin1 complex formation during mouse skin papilloma development Carcinogenesis 2009, 30, 1620-1627 10.1093/carcin/bgp168
26. 2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and β-arrestin1-dependent signaling pathways J. Biol. Chem. 2010, 285, 39672-39681 10.1074/jbc.M110.117689
27. 2-induced human mesenchymal stem cells migration and proliferation J. Cell. Physiol. 2011, 226, 559-571 10.1002/jcp.22366
28. Kambe, T.; Maruyama, T.; Nakai, Y.; Yoshida, H.; Oida, H.; Maruyama, T.; Abe, N.; Nishiura, A.; Nakai, H.; Toda, M. Discovery of novel prostaglandin analogs as potent and selective EP2/EP4 dual agonists Bioorg. Med. Chem. 2012, 20, 2235-2251 10.1016/j.bmc.2012.02.018
29. Roy, A. J.; Kalarmazoo, M. Enlarged-hetero-ring prostacyclin analogs. U.S. Patent US4490537, 1977.
30. Path Hunter assay (DiscoveRX homepage). https://www.discoverx.com/arrestin (accessed Nov 12, 2015).
31. Rajagopal, S.; Ahn, S.; Rominger, D. H.; MacDonald, W. G.; Lam, C. M.; DeWire, S. M.; Violin, J. D.; Lefkowitz, R. J. Quantifying Ligand Bias at Seven-Transmembrane Receptors Mol. Pharmacol. 2011, 80, 367-377 10.1124/mol.111.072801